7Deferrari G, Ravera M, Berrativ, et al. Optimizing therapy in the diabetic patient with renal disease antihypertensive treatment [ J ]. J Am Soc Nephro,2004,15 ( 1 ) :56.
7[1]Johnston C I, Risvanis J. Preclinical pharmacology of angiotensin Ⅱ receptor antagonists: Update and outstanding issues[J]. Am J Hypertens, 1997,10(12 Pt 2):306-10.
8[2]Unger T, Culman J, Gohlke P. Angiotensin Ⅱ receptor blockade and end-organ protection: Pharmacological rationale and evidence[J]. J Hypertens, 1998,16(Suppl7):3-9.
9[3]Glassman H N, Kleinert H D, Boger R S, et al. Clinical pharmacology of Enalkiren, a novel dipeptide renin inhibitor[J]. J Cardiovasc Pharmacol, 1991,16(Supp l4):576.
10[4]Clozel J P, Fischli W. Comparative effects of three diff- erent potent renin inhibitiors in primates[J]. Hypertension, 1993,22:9.
